Aradigm Corporation

Genentech, Inc.

University of California

Acrux Dds Pty Ltd

Oregon State University

Novo Nordisk A/s

Grifols, S.a.

Igor Gonda

Reid M Rubsamen

Stephen J Farr

David C Cipolla

Jeffrey A Schuster

Rajesh S Patel

James Blanchard

Adam Watkinson

Homer A Boushey

Nina Wilkins

Kerrie Setiawan

Luiz Eduardo Moreira Bermudez

Tony Dipietro

Andrew Humberstone

Steven J Shire

Suzanne Sin-Mui Lo Weck

Hak-Kim Chan

Peter M Lloyd

Sudarsan Srinivasan

Russell M Pon

Andrew Reginald Clark

Hans Schreier

Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.

Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria

Methods for formulating and compositions of immediate and sustained release liposomal products which comprise a surfactant that interacts with liposomes to effect drug release therefrom, and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.

Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile

Methods for formulating a liposome comprised of a surfactant and a cryopreservative that can be frozen for long term stability, and upon thawing provides an immediate and sustained release delivery profile. Specific liposome formulations include anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.

Liposomal formulations that form drug nanocrystals after freeze-thaw

The invention provides a method of detecting abnormal entry of gastrointestinal contents into the respiratory tract of a patient. The method comprises orally administering to a subject formulation comprising a detectable label that is not absorbed from the gastrointestinal tract but can be absorbed from the respiratory tract. The extent of the gastrointestinal contents entering the respiratory tract can be estimated by measuring the level of the detectable label in a body fluid, e.g., blood or urine.

Diagnosis of entry of gastrointestinal contents into respiratory tract of humans and animals

Liposomal ciprofloxacin formulations with encapsulated ciprofloxacin nanocrystals

A method of diagnosing in a subject for the purpose of determining if the subject's gastrointestinal contents has entered the subject's respiratory tract. The qualitative analysis can be also expanded into quantitative analysis, enabling the estimation of either the concentration, or the amount, or both, of the gastrointestinal contents that entered the respiratory tract. The invention also provides methods of treatment based on the identification of aspiration using the methods of the invention.

Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract

The invention provides a method of diagnosing entry of gastrointestinal contents into the respiratory tract of a patient suffering from reflux disease. The method comprises orally administering to a subject formulation comprising a detectable label that is not absorbed from the gastrointestinal tract but can be absorbed from the respiratory tract. The extent of the gastrointestinal contents entering the respiratory tract can be estimated by measuring the level of the detectable label in a body fluid, e.g., blood or urine.

The invention is directed to a transdermal drug delivery composition which includes at least one physiologically active agent; and at least one volatile solvent; and at least one viscosity modulating agent. The invention extends to methods of administering such a composition to a subject and treatment of subjects using the composition.

Method and composition for transdermal drug delivery

The invention relates generally to a system and method for treating conditions responsive to nicotine therapy. More specifically, the invention relates to pulmonary administration of a nicotine containing formulation to effect smoking cessation.

Systems and methods for effecting cessation of tobacco use

Growing community of inventors

San Francisco, CA, United States of America

Igor Gonda